Does contegra xenograft implantation evoke cellular immunity in children?

Related Experiment Video

Updated: Jul 13, 2026

Xenograft Skin Model to Manipulate Human Immune Responses In Vivo
08:23

Xenograft Skin Model to Manipulate Human Immune Responses In Vivo

Published on: June 29, 2022

Michal Wojtalik1, Wojciech Mrowczynski, Jan Zeromski

  • 1Department of Paediatric Cardiac Surgery, Karol Marcinkowski University of Medical Sciences, 27/33 Szpitalna strasse Poznan 60-572, Poland.

Interactive Cardiovascular and Thoracic Surgery
|August 3, 2007
PubMed

Insights

Children receiving bovine valved conduits showed increased B-cells and T-lymphocyte activation, suggesting cellular and humoral immunity against the xenograft. Further research is needed to determine the impact on graft survival.

Area of Science:

  • Immunology
  • Cardiovascular Surgery

Background:

  • Right ventricle outflow tract reconstruction often requires prosthetic materials.
  • Bovine valved conduits are used in pediatric cardiac surgery.
  • Assessing immune responses to xenografts is crucial for long-term outcomes.

Purpose of the Study:

  • To investigate changes in peripheral blood lymphocyte subpopulations and activation in children receiving bovine valved conduits.
  • To evaluate cellular immunity against xenografts post-implantation.
  • To explore potential indicators of humoral and cellular immune responses.

Main Methods:

  • A cohort study comparing 19 pediatric patients with xenografts to a control group.
  • Flow cytometry used to analyze lymphocyte immunophenotype and T-cell activation preoperatively and at 3, 6, and 12 months post-operation.
  • Quantification of CD3+, CD4+, CD8+, natural killer cells, B-cells, CD69+, and CD71+ cells.

Main Results:

  • No significant differences in CD3+, CD4+, CD8+, or natural killer cell counts between groups.
  • A notable increase in B-cell percentages (15.5% to 23%) observed between 3 and 6 months post-implantation.
  • Elevated levels of activated T-lymphocytes (CD69+ and CD71+ cells) at 12 months in xenograft recipients compared to controls.

Conclusions:

  • Xenograft recipients demonstrated increased B-cell counts, potentially indicating humoral immune activation.
  • Higher numbers of activated T-lymphocytes suggest a cellular immune response to the bovine valved conduit.
  • The clinical significance of these immune changes on graft survival requires further investigation.

More Related Videos

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR06:06

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR

Published on: May 23, 2019

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...